Reneo Pharmaceuticals, Inc. (RPHM)
NASDAQ: RPHM · IEX Real-Time Price · USD
5.86
+0.15 (2.63%)
At close:
Mar 20, 2023, 4:00 PM
5.57
-0.29 (-4.95%)
After-hours:
Mar 20, 2023, 7:21 PM EDT
Company Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases.
It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V.
Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Reneo Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Mr. Gregory J. Flesher |
Contact Details
Address:
18575 Jamboree Road, Suite 275-s Irvine, California 92612 United States | |
| Phone | (858) 283-0280 |
| Website | reneopharma.com |
Stock Details
| Ticker Symbol | RPHM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001637715 |
| CUSIP Number | 75974E103 |
| ISIN Number | US75974E1038 |
| Employer ID | 47-2309515 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Grey | Founder and Executive Chairman |
| Gregory J. Flesher | President, Chief Executive Officer and Director |
| Michael P. Cruse | Chief Operating Officer |
| Vineet R. Jindal | Consultant |
| Jennifer P. Lam | Principal Financial and Accounting Officer |
| Wendy S. Johnson M.B.A. | Consultant |
| Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer |
| Lynn Purkins Ph.D. | Senior Vice President of Clinical Operations |
| Ashley F. Hall J.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2023 | 8-K | Current Report |
| Mar 10, 2023 | 8-K | Current Report |
| Jan 9, 2023 | 8-K | Current Report |
| Nov 8, 2022 | 10-Q | Quarterly Report |
| Nov 8, 2022 | 8-K | Current Report |
| Sep 30, 2022 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 11, 2022 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 9, 2022 | 10-Q | Quarterly Report |
| Aug 9, 2022 | 8-K | Current Report |
| Aug 2, 2022 | 8-K | Current Report |